We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 19, 2022

Role of Stem Cell Transplant in CD30+ PTCL After Frontline Brentuximab Vedotin+CHP or CHOP

Blood Advances


Additional Info

Blood Advances
Role of Stem Cell Transplant in CD30-positive PTCL following Frontline Brentuximab Vedotin+CHP or CHOP in ECHELON-2
Blood Adv 2022 Apr 25;[EPub Ahead of Print], KJ Savage, SM Horwitz, R Advani, JH Christensen, E Domingo-Domenech, G Rossi, F Morschhauser, O Alpdogan, C Suh, K Tobinai, A Shustov, M Trneny, SLS Yuen, PL Zinzani, LH Truemper, TM Illidge, OA O'Connor, B Pro, H Miao, V Bunn, K Fenton, M Fanale, M Puhlmann, SP Iyer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading